Picroside II,the major active component of picroside,has been shown to induce PC12 cell axonal growth and relieve free radical damage.In vivo experiments have demonstrated that picroside II can improve neurological fu...Picroside II,the major active component of picroside,has been shown to induce PC12 cell axonal growth and relieve free radical damage.In vivo experiments have demonstrated that picroside II can improve neurological function in rats with cerebral ischemia/reperfusion injuries.In the present in vivo study,enzyme-linked immunosorbent assay and immunohistochemistry revealed that picroside II increased superoxide dismutase content and reduced inducible nitric oxide synthase content in the ischemic hemisphere.The effects of picroside II were similar to those of salvianic acid A sodium,an active control drug.These results indicate that picroside II exerts a neuroprotective effect,possibly by downregulating inducible nitric oxide synthase expression,increasing superoxide dismutase activity,and inhibiting neuronal apoptosis.展开更多
目的:优选丹参素钠-聚乳酸-羟基乙酸共聚物(PLGA)缓释微球的处方工艺并考察其药剂学性能。方法:采用W/O/O型乳化溶剂挥发法制备丹参素钠-PLGA微球,以载药量、包封率及收率为考察指标,通过单因素试验优选处方工艺,并考察其体外释药性能...目的:优选丹参素钠-聚乳酸-羟基乙酸共聚物(PLGA)缓释微球的处方工艺并考察其药剂学性能。方法:采用W/O/O型乳化溶剂挥发法制备丹参素钠-PLGA微球,以载药量、包封率及收率为考察指标,通过单因素试验优选处方工艺,并考察其体外释药性能。采用激光粒度分析仪、扫描电子显微镜和X射线衍射法对该微球进行表征。结果:选取内水相体积300μL,PLGA质量浓度125 g·L^(-1),二氯甲烷-丙酮(3∶7),外油相为液体石蜡200 m L,加入正己烷6 m L,0.25%司盘80为乳化剂,1 400 r·min^(-1)搅拌4 h。丹参素钠-PLGA微球平均载药量(20.71±1.42)%,平均包封率(63.27±1.70)%,平均收率(99.10±0.83)%,体外累积释放率达98%需要120 h。平均粒径(71.72±1.71)μm,表面圆整光滑,内部含有蜂窝状孔洞。部分药物可能以晶体状态分散于载体材料中。结论:W/O/O型乳化溶剂挥发法成功制备了丹参素钠-PLGA微球,优选的处方工艺稳定合理,可为丹参素钠制剂的开发提供参考。展开更多
基金the National Natural Science Foundation of China, No. 30873391, 81041092
文摘Picroside II,the major active component of picroside,has been shown to induce PC12 cell axonal growth and relieve free radical damage.In vivo experiments have demonstrated that picroside II can improve neurological function in rats with cerebral ischemia/reperfusion injuries.In the present in vivo study,enzyme-linked immunosorbent assay and immunohistochemistry revealed that picroside II increased superoxide dismutase content and reduced inducible nitric oxide synthase content in the ischemic hemisphere.The effects of picroside II were similar to those of salvianic acid A sodium,an active control drug.These results indicate that picroside II exerts a neuroprotective effect,possibly by downregulating inducible nitric oxide synthase expression,increasing superoxide dismutase activity,and inhibiting neuronal apoptosis.
文摘目的:优选丹参素钠-聚乳酸-羟基乙酸共聚物(PLGA)缓释微球的处方工艺并考察其药剂学性能。方法:采用W/O/O型乳化溶剂挥发法制备丹参素钠-PLGA微球,以载药量、包封率及收率为考察指标,通过单因素试验优选处方工艺,并考察其体外释药性能。采用激光粒度分析仪、扫描电子显微镜和X射线衍射法对该微球进行表征。结果:选取内水相体积300μL,PLGA质量浓度125 g·L^(-1),二氯甲烷-丙酮(3∶7),外油相为液体石蜡200 m L,加入正己烷6 m L,0.25%司盘80为乳化剂,1 400 r·min^(-1)搅拌4 h。丹参素钠-PLGA微球平均载药量(20.71±1.42)%,平均包封率(63.27±1.70)%,平均收率(99.10±0.83)%,体外累积释放率达98%需要120 h。平均粒径(71.72±1.71)μm,表面圆整光滑,内部含有蜂窝状孔洞。部分药物可能以晶体状态分散于载体材料中。结论:W/O/O型乳化溶剂挥发法成功制备了丹参素钠-PLGA微球,优选的处方工艺稳定合理,可为丹参素钠制剂的开发提供参考。
